Search
Search
Arshad Khanani, MD
Show Description +
Arshad Khanani, MD, provides an overview of data from the phase 2a TIME-2 study, which looked at twice-a-day dosing of subcutaneous 15 mg AKB-9778 as monotherapy and in combination with 0.3 mg ranibizumab (Lucentis, Genentech) for the treatment of diabetic eye disease. He points out that the most important finding of the study is that fellow eyes exposed to AKB-9778 had almost three times the improvement in diabetic retinopathy severity scale compared with eyes in the placebo arm. The takeaway? The TIME-2 data shows that AKB-9778 can be a future treatment for patients with diabetic retinopathy in both eyes.
Posted: 8/03/2016
Arshad Khanani, MD
Arshad Khanani, MD, provides an overview of data from the phase 2a TIME-2 study, which looked at twice-a-day dosing of subcutaneous 15 mg AKB-9778 as monotherapy and in combination with 0.3 mg ranibizumab (Lucentis, Genentech) for the treatment of diabetic eye disease. He points out that the most important finding of the study is that fellow eyes exposed to AKB-9778 had almost three times the improvement in diabetic retinopathy severity scale compared with eyes in the placebo arm. The takeaway? The TIME-2 data shows that AKB-9778 can be a future treatment for patients with diabetic retinopathy in both eyes.
Posted: 8/03/2016
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASRS: 2016.
Please log in to leave a comment.